Raoul S. Concepcion, MD, FACS, Author at Grand Rounds in Urology

Raoul S. Concepcion, MD, FACS

The Comprehensive Prostate Center

Nashville, TN

Raoul S. Concepcion, MD, FACS, is the current Director of The Comprehensive Prostate Center in Nashville, TN, and also has an appointment as Clinical Associate Professor of Urology, Vanderbilt University School of Medicine. He served as a resident in General Surgery and Urology at Vanderbilt from 1984 – 1990. Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past president of LUGPA and, along with two other urologists, founded CUSP, a urologic research consortium in the United States. Additionally, he serves as the Chief Urologic Clinical Officer for Integra Connect (West Palm Beach, FL), is an advisor or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and is the current editor for Urologists in Cancer Care.

Articles by Raoul S. Concepcion, MD, FACS

Current Challenges in Upper Tract Urothelial Cancer

Posted by Raoul S. Concepcion, MD, FACS | Oct 2018

Raoul S. Concepcion, MD, FACS, provides a brief overview of the background, incidence, and epidemiology of upper tract urothelial carcinoma (UTUC). He then discusses indications for nephroureterectomy with a cuff of bladder and possible methods for management that would be less invasive for low-grade UTUC patients.

Updates on Upper Tract Urothelial Cancer

Posted by Raoul S. Concepcion, MD, FACS | Oct 2018

Raoul S. Concepcion, MD, FACS, discusses the challenge of managing upper tract urothelial cancer (UTUC) while avoiding overtreatment. Although nephroureterectomy is an appropriate treatment for high grade tumors, urologists should utilize localized therapy and avoid surgery in low-grade UTUC.

Immunotherapy 101 for the Urologist

Posted by Raoul S. Concepcion, MD, FACS | Apr 2018

Raoul S. Concepcion, MD, summarizes the mechanism of action behind the immune response to cancer. He also provides an update on the current and emerging immunotherapies for cancer treatment, including vaccines, checkpoint inhibitors, CAR T-cell therapies, viral vectors, and adoptive cell therapy.

Ask the Expert: What Combinations of Immunotherapy for Prostate Cancer Are Most Promising?

Posted by Raoul S. Concepcion, MD, FACS | Nov 2017

Raoul S. Concepcion, MD, FACS, discusses managing prostate cancer with a combination of immunotherapeutic agents and other treatment options. Sipuleucel-T (PROVENGE), the only FDA approved immunotherapy for metastatic castration-resistant prostate cancer (mCRPC), does not attack androgen receptors. Therefore, Dr. Concepcion explores the possibility combining sipuleucel-T with androgen excess inhibitors, like abiraterone or enzalutamide, or a sipuleucel-T/radium-223 combination.

What Tools Can Be Used to Predict Who Will Respond to Certain Prostate Cancer Drugs?

Posted by Raoul S. Concepcion, MD, FACS | Oct 2017

Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses if there...